A milestone in the fight against dengue fever: Island Pharmaceuticals (ASX:ILA) advances ISLA-101 clinical trials

In a significant stride forward for antiviral drug development, Melbourne-based Island Pharmaceuticals (ASX:ILA) has reached a pivotal milestone in its PROTECT clinical trial.

The company has completed the enrolment of all ten participants in the Phase 2b arm of its Phase 2a/b study, which investigates the potential of its lead candidate, ISLA-101, in combating dengue fever—a mosquito-borne disease afflicting millions annually.

Highlights:

• Phase 2b enrolment completed: All ten subjects are now participating in the therapeutic arm, focusing on reducing symptoms in those already infected.
• Dual-purpose investigation: The study evaluates ISLA-101’s efficacy as both a prophylactic (Phase 2a) and therapeutic (Phase 2b) treatment.
• Safety and antiviral activity confirmed: Progression to Phase 2b followed recommendations by the Safety Review Committee and approval from the US FDA.
• Results timeline: High-level Phase 2b results are expected by April 2025, with comprehensive data from both study arms anticipated in Q4 FY2025.

Strategic Significance

ISLA-101 is a repurposed drug with a well-documented safety profile, providing a promising avenue for addressing dengue fever’s unmet medical needs.

The repurposing approach allows Island to leverage existing data, accelerating development timelines and reducing costs.

Island Pharmaceuticals Managing Director and CEO, Dr David Foster, underscored the importance of this achievement:

“The enrolment of the final six subjects in the Phase 2b therapeutic arm is a significant advancement in our clinical trial, and towards better understanding the potential of ISLA-101 as a treatment for dengue fever.”

This milestone not only highlights Island’s commitment to innovative healthcare solutions but also strengthens its positioning in the global antiviral market.

A successful outcome could pave the way for a Priority Review Voucher from the FDA—an asset that could expedite future approvals or be sold in secondary markets.

A Global Context

With no specific antiviral treatment available for dengue fever, ISLA-101 has the potential to fill a critical void.

The disease, which is endemic to over 100 countries, continues to pose a significant public health challenge.

Island’s research thus holds the promise of not just mitigating the disease’s impact but also contributing to the broader fight against vector-borne illnesses.

Looking Ahead

As the world awaits the trial results, Island Pharmaceuticals exemplifies how strategic drug repurposing can lead to impactful healthcare innovations.

Investors and stakeholders alike will be closely monitoring the next phase of development, as it could herald a new era in the treatment of dengue fever and similar diseases.